Japan is one of most innovative drug manufacturer-friendly countries because it revised its patent and drug regulation systems for providing patent and non-patent incentives for new use and treatment R&D based on its pro-patent and pro-medical science policies. This article provides an overview of the pharmaceutical industry and examines patent and non-patent incentives for drug R&D in focusing on incentives for developing new uses of and treatments for known drugs from a comparative law perspective. After discussing the difficulties in establishing infringement and in obtaining injunctions against generic drug manufacturers who infringe new use product patents, the article reviews measure Japanese scholars have proposed to help secure ince...
Innovation does not stop when new medicines are launched. Companies with approved drugs and biologic...
Recent changes made to Japanese and American patent procedural laws have not addressed the contentio...
The cost of medicines imposes a significant financial burden on society, with New Zealand spending $...
With the passage of the Drug Price Competition Act of 1984 in the United States, the recent German S...
This Article will look at the impact of the new Japanese legislation on patent infringement damages ...
In Japan, the research and development (R&D) process of a new drug, from synthesizing new compounds ...
Accordingly, this Article will look at the impact of the new Japanese legislation on patent infringe...
The patent laws of the United States and Japan contain provisions that permit the experimental use o...
Kazunari Sugimitsu,1,2 Yoshinobu Manome2 1Graduate School of Innovation Management, Kanazawa Institu...
The following is a translation of “Patent Protection of Medical Methods—Focusing on Ethical Issues,”...
The manufacturing side of the pharmaceutical industry has been neglected in innovation theory and po...
The chapter investigates the returns to R&D expenditures on patenting in the pharmaceutical industry...
This article reexamines the sources of exclusivity for drugs, considers their limitations, and evalu...
The Japanese pharmaceutical market is one of the largest in the world. The Japanese government has i...
TSince current Japanese patent law was enacted in 1959, it has been revised several times, mainly fo...
Innovation does not stop when new medicines are launched. Companies with approved drugs and biologic...
Recent changes made to Japanese and American patent procedural laws have not addressed the contentio...
The cost of medicines imposes a significant financial burden on society, with New Zealand spending $...
With the passage of the Drug Price Competition Act of 1984 in the United States, the recent German S...
This Article will look at the impact of the new Japanese legislation on patent infringement damages ...
In Japan, the research and development (R&D) process of a new drug, from synthesizing new compounds ...
Accordingly, this Article will look at the impact of the new Japanese legislation on patent infringe...
The patent laws of the United States and Japan contain provisions that permit the experimental use o...
Kazunari Sugimitsu,1,2 Yoshinobu Manome2 1Graduate School of Innovation Management, Kanazawa Institu...
The following is a translation of “Patent Protection of Medical Methods—Focusing on Ethical Issues,”...
The manufacturing side of the pharmaceutical industry has been neglected in innovation theory and po...
The chapter investigates the returns to R&D expenditures on patenting in the pharmaceutical industry...
This article reexamines the sources of exclusivity for drugs, considers their limitations, and evalu...
The Japanese pharmaceutical market is one of the largest in the world. The Japanese government has i...
TSince current Japanese patent law was enacted in 1959, it has been revised several times, mainly fo...
Innovation does not stop when new medicines are launched. Companies with approved drugs and biologic...
Recent changes made to Japanese and American patent procedural laws have not addressed the contentio...
The cost of medicines imposes a significant financial burden on society, with New Zealand spending $...